placebo

Related by string. placebos * * blind placebo controlled . placebo controlled . randomized placebo controlled . double blind placebo . placebo controlled clinical trials . blind randomized placebo . placebo p . placebo p = . placebo controlled trials . inactive placebo . blinded placebo controlled . placebo controlled randomized . placebo controlled studies . placebo controlled clinical *

Related by context. All words. (Click for frequent words.) 73 mg dose 72 placebo p = 72 inactive placebo 70 placebos 70 dummy pills 69 dummy pill 69 placebo p 68 adalimumab 67 p = #.# [002] 67 mg BID 66 mitoxantrone 66 mg kg 66 #mg dose [003] 66 oxycodone CR 66 mg QD 66 mg 66 tiotropium 66 desvenlafaxine succinate 66 randomized 65 dexamethasone 65 FOLFOX 65 5-FU/LV 65 mg d 65 p = #.# [004] 65 lopinavir r 65 mcg 65 p = 65 etanercept 65 LPV r 64 insulin detemir 64 olanzapine 64 #mg/day [001] 64 inert placebo 64 azathioprine 64 unfractionated heparin 64 pioglitazone 64 placebo capsules 64 fluoxetine 64 mcg BID 64 P = .# 64 peginterferon alfa 2b 64 chlorambucil 64 n = 64 tapentadol ER 64 mcg kg 64 triamcinolone 63 lispro 63 mg ustekinumab 63 plus methotrexate 63 sham acupuncture 63 lamivudine 63 pregabalin 63 achieved statistical significance 63 saline placebo 63 enoxaparin 63 comparator arm 63 #mg doses [002] 63 solifenacin 63 #mg/day [002] 63 milligram doses 63 statistically significant improvement 63 active comparator 63 mg TID 63 μg 63 esomeprazole 63 mg kg dose 63 quetiapine 62 mg doses 62 mcg dose 62 peginterferon alfa 2a 62 virologic failure 62 APTIVUS r 62 ABC/3TC 62 adjunctive placebo 62 zolmitriptan 62 valacyclovir 62 NPH insulin 62 adefovir 62 fluorouracil 62 TDF FTC 62 monotherapy 62 mg Lucentis 62 mcg QD 62 FOLFOX4 62 #mg/kg [002] 62 lopinavir r arm 62 primary endpoint 62 achieved ACR# 61 mg simvastatin 61 Peg IFN 61 glimepiride 61 nortriptyline 61 RLAI 61 atazanavir ritonavir 61 montelukast 61 insulin glargine 61 tamsulosin 61 placebo dexamethasone 61 methotrexate 61 abacavir lamivudine 61 demonstrated statistically significant 61 saline injections 61 statistically significant 61 valsartan 61 molindone 61 plus ribavirin 61 LEXIVA r 61 peginterferon 61 #mg dose [001] 61 lamotrigine 61 cabazitaxel 61 discontinuations due 61 idraparinux 61 clopidogrel 61 irbesartan 61 HbA1c levels 61 docetaxel 61 fluticasone 61 pravastatin 61 ibandronate 61 valproate 61 methotrexate monotherapy 61 donepezil 61 #mg BID [003] 61 cilostazol 61 intramuscularly 61 amoxicillin clavulanate 61 TEAEs 61 Pred Forte 60 4mg/kg 60 PREZISTA r 60 ATACAND 60 interferon alfa 2b 60 #mg QD [001] 60 clodronate 60 #mg BID [001] 60 tipranavir r 60 8mg/kg 60 nasopharyngitis 60 tolterodine ER 60 pramipexole 60 FOLFOX4 alone 60 glargine 60 adjunctive ABILIFY 60 candesartan 60 mcg albinterferon alfa 2b 60 mycophenolate mofetil 60 LEXIVA 60 nonsignificant 60 infliximab 60 plus MTX 60 lopinavir ritonavir 60 ramipril 60 mg RDEA# 60 oxycodone IR 60 tenofovir emtricitabine 60 zoledronic acid 60 sertraline 60 timepoint 60 sustained virologic response 60 ziprasidone 60 tirofiban 60 secondary endpoint 60 primary efficacy endpoint 60 median PFS 60 certolizumab 60 CANCIDAS 60 allopurinol 59 plus dexamethasone 59 Lucentis monotherapy 59 citalopram 59 mcg doses 59 nelfinavir 59 p = NS 59 rimonabant #mg 59 dummy capsules 59 mg subcutaneously 59 risedronate 59 Engerix B 59 nonresponders 59 atazanavir 59 dapagliflozin plus 59 statistically significant reduction 59 placebo controlled 59 milligram dose 59 salmeterol fluticasone 59 mg tid 59 ritonavir boosted 59 chlorthalidone 59 carvedilol 59 #mg QD [002] 59 copies mL 59 μg dose 59 bolus injection 59 urate lowering therapy 59 pegylated interferon alfa 2b 59 treatment emergent adverse 59 administered subcutaneously 59 dosing 59 lumbar spine BMD 59 bosentan 59 rotigotine 59 gemcitabine 59 MADRS score 59 receiving ISENTRESS 59 μg kg 59 venlafaxine XR 58 receiving VICTRELIS 58 tolerability 58 Q2W 58 salmeterol 58 bezafibrate 58 nifedipine 58 raltegravir 58 risperidone 58 octreotide LAR 58 virologic response 58 pegylated liposomal doxorubicin 58 Lamictal XR 58 interferon alfa 58 non inferiority 58 confidence interval CI 58 timepoints 58 FOLFIRI 58 oral olanzapine 58 ribavirin RBV 58 PEG Intron 58 abciximab 58 efavirenz EFV 58 nadroparin 58 IFN alfa 58 sirolimus eluting stent 58 clopidogrel Plavix 58 #mg [003] 58 secondary endpoints 58 eribulin 58 LVEF 58 pegylated interferon 58 PREZISTA ritonavir 58 oral diclofenac 58 randomized #:# 58 nonfatal MI 58 spontaneous bowel movements 58 budesonide pMDI 58 olmesartan 58 paricalcitol 58 CR nPR 58 oral prednisone 58 Psoriasis Area 58 zonisamide SR 58 bupropion SR 58 metformin 58 NATRECOR R 58 severe hypoglycemic 58 venlafaxine 58 tolvaptan 58 ACTEMRA TM 58 sumatriptan naproxen sodium 58 carboplatin paclitaxel 58 severe exacerbations 58 DAPT 58 placebo fluoxetine 58 levetiracetam 58 ezetimibe simvastatin 58 incontinence episodes 58 FOLFIRI alone 58 daunorubicin 58 fondaparinux 58 cholinesterase inhibitor 58 febrile neutropenia 57 weekly subcutaneous injections 57 diuretic chlorthalidone 57 ULORIC 57 amiodarone 57 dexmedetomidine 57 pyridostigmine 57 aripiprazole 57 viral suppression 57 steroid dexamethasone 57 fluticasone salmeterol 57 statistically significant p 57 lacosamide 57 glyburide 57 metformin IR 57 Cmax 57 #mg/m# [002] 57 randomized placebo controlled 57 ACR# response 57 tacrolimus ointment 57 subcutaneous injections 57 avosentan 57 divalproex sodium 57 rizatriptan 57 vancomycin 57 fluticasone propionate 57 eplerenone 57 tapentadol IR 57 #.#mg [004] 57 tamoxifen 57 eptifibatide 57 telmisartan 57 fluconazole 57 vicriviroc 57 insulin lispro 57 plus gemcitabine 57 subcutaneously administered 57 benazepril 57 μmol L 57 prednisone prednisolone plus 57 biphasic insulin aspart 57 topotecan 57 evaluable 57 oral rivaroxaban 57 QD dosing 57 tumor shrinkage 57 progression TTP 57 goserelin 57 selegiline 57 ddI 57 anticholinergics 57 zidovudine lamivudine 57 titrated glipizide 57 TNF inhibitor 57 undetectable viral load 57 mcg mL 57 leuprorelin 57 events AEs 57 bevacizumab 57 prednisone 57 definite stent thrombosis 57 randomly assigned 57 neostigmine 57 apremilast 57 KAPIDEX 57 levosimendan 57 postoperatively 57 composite endpoint 57 divalproex 57 baseline HbA1c 57 ticagrelor 57 dutasteride 57 racemic albuterol 57 mg dL 57 Viread Emtriva 57 concomitant medications 57 Adverse events 57 N acetylcysteine 57 bortezomib 57 5FU 57 ZOMIG Nasal Spray 57 bupropion 57 dacarbazine 57 pramlintide 57 8mg 57 3mg/kg 57 anastrozole 57 DMARD 57 conjugated equine estrogen 56 recurrent VTE 56 hypokalemia 56 CIMZIA TM 56 deferoxamine 56 tipranavir 56 achieved PASI 56 antihypertensive medications 56 subcutaneous enoxaparin 56 clomipramine 56 statistically significant p = 56 levodopa 56 imatinib 56 doxorubicin docetaxel 56 budesonide 56 OADs 56 captopril 56 ritonavir boosted atazanavir 56 HBeAg negative patients 56 acarbose 56 FOLPI 56 Perforomist Inhalation Solution 56 degarelix 56 efavirenz 56 leukopenia 56 symptom severity 56 ketorolac 56 TMC# [001] 56 gemifloxacin 56 plus medroxyprogesterone acetate 56 alendronate 56 antihypertensive therapy 56 eszopiclone 56 reach statistical significance 56 beclomethasone dipropionate 56 letrozole 56 subcutaneous insulin 56 IIIa inhibitors 56 glucose lowering 56 docetaxel chemotherapy 56 experienced virologic failure 56 PASI scores 56 ritonavir boosted lopinavir 56 ARB telmisartan 56 FOSRENOL ® 56 tocilizumab 56 dalteparin 56 leucovorin 56 mcg Albuferon 56 enalapril 56 rosuvastatin 56 thromboembolic events 56 #.#mg/dL 56 ropinirole 56 interferon alfa 2a 56 XELOX 56 statin 56 reinfarction 56 glulisine 56 VIRAMUNE 56 aprepitant 56 HBeAg seroconversion 56 ranibizumab 56 vandetanib 56 statistically significant differences 56 lamivudine monotherapy 56 dose regimens 56 glatiramer acetate 56 aspirin clopidogrel 56 decitabine 56 quetiapine risperidone 56 rosuvastatin #mg 56 3TC 56 oxcarbazepine 56 carboplatin 56 undetectable HCV RNA 56 alteplase 56 fosamprenavir 56 PANSS scores 56 nonsignificant difference 56 febuxostat 56 candesartan cilexetil 56 56 Viread Emtriva Sustiva 56 Flu Cy 56 % CI #.#-#.# [003] 56 AGILECT R 56 primary endpoints 56 #.#/#.# mmHg [001] 56 % CI #.#-#.# [002] 56 peg IFN 56 placebo dummy pill 56 Doxil ® 56 mg Proellex 56 mg/m2 dose 56 duloxetine 56 doxazosin 56 levofloxacin 56 leuprolide 56 pamidronate 56 dosed 56 CsA 56 rivaroxaban 56 Taxotere 56 Crestor rosuvastatin 56 REBETOL 56 Median survival 56 pegylated interferon alfa 2a 56 ORENCIA 56 cerebrovascular events 56 prespecified 56 bupivacaine 56 ALVESCO 56 #μg [002] 56 blinded placebo 56 mometasone 56 RLS symptoms 56 ug dose 56 #ug [001] 56 pegaptanib 56 amlodipine 56 darunavir ritonavir 56 HbA1c 56 dyspnea 56 cobicistat 56 μg doses 56 piperacillin tazobactam 55 remifentanil 55 REYATAZ r arm 55 CIMZIA TM certolizumab pegol 55 sham injections 55 #mg/m# [001] 55 virological failure 55 risperidone Risperdal 55 serum phosphorus 55 SSRI citalopram 55 amprenavir 55 mg eq 55 teriflunomide 55 #mg dosing 55 randomized #:#:# 55 PREZISTA rtv 55 Folfox 55 ug kg 55 virologically 55 HbA 1c levels 55 capecitabine 55 rhTSH 55 Fludara 55 TMC# r 55 neurologic progression 55 atorvastatin #mg 55 clinically meaningful 55 transaminase elevations 55 Pegasys plus Copegus 55 -#.# mg dL [002] 55 tolterodine 55 antiandrogen 55 systolic BP 55 randomization 55 EBRT 55 nicardipine 55 infliximab monotherapy 55 acute gout flares 55 sirolimus 55 ximelagatran 55 HAM D# 55 CCyR 55 q#h 55 mg/# mg [001] 55 FDA defined valvulopathy 55 #mg BID [002] 55 ropivacaine 55 thiazide diuretics 55 oral allopurinol 55 3mg 55 plasma concentrations 55 Aptivus ® 55 protease inhibitor PI 55 caspofungin 55 ribavirin 55 hours postdose 55 indinavir 55 miconazole 55 clinically meaningful improvement 55 Elitek 55 glipizide 55 g dL 55 CI -#.# 55 antidepressant therapy 55 tacrolimus 55 rituximab 55 intermittent dosing 55 Bicalutamide 55 ramelteon 55 paroxetine 55 MMSE scores 55 posaconazole 55 bolus dose 55 bivalirudin 55 free survival PFS 55 comparator PI r 55 virologic breakthrough 55 splenectomized patients 55 flutamide 55 erlotinib 55 ALIMTA cisplatin 55 Montgomery Asberg Depression 55 certolizumab pegol 55 Navelbine 55 gout flares 55 vinorelbine 55 ipsilateral stroke 55 iodixanol 55 incidence ≥ 55 sulfasalazine 55 ARCOXIA 55 sunitinib 55 AZILECT 55 IR prednisone 55 ACE inhibitor ramipril 55 timolol 55 Rating Scale MADRS 55 zoledronate 55 dose cytarabine 55 evaluable patients 55 cabergoline 55 sorafenib 55 tibolone 55 escitalopram 55 mg qd 55 norethindrone 55 EMEND 55 #.#g/day 55 placebo controlled trials 55 isoproterenol 55 mg/# hr 55 ketoconazole 55 Median PFS 55 IBS symptoms 55 PegIntron 55 imipramine 55 linezolid 55 HDRS 55 #:# randomization 55 unsupplemented 55 nondiabetic patients 54 ancrod 54 1mg 54 #mg [001] 54 alfa 2a 54 dexamethasone Decadron 54 Viread Emtriva SUSTIVA 54 pegylated interferon alpha 54 untreated mice 54 IM progesterone 54 mcg linaclotide 54 mg Pycnogenol 54 d4T 54 headache nasopharyngitis 54 FEV1 54 abdominal pain abdominal discomfort 54 gadobutrol 54 IELT 54 enfuvirtide 54 dose colchicine 54 randomisation 54 Paxil paroxetine 54 SVR# 54 Pegasys ® 54 β blockers 54 simulated acupuncture 54 buspirone 54 simvastatin 54 temsirolimus 54 mitoxantrone plus 54 3TC lamivudine Epivir 54 PREMPRO 54 severe neutropenia 54 intravenous cyclophosphamide 54 ng dl 54 dosage regimens 54 mesalamine 54 hsCRP levels 54 events TEAEs 54 ARIXTRA 54 placebo controlled clinical trials 54 detemir 54 conjugated equine estrogens 54 DAS# remission 54 dobutamine 54 intravenous bisphosphonates 54 mg m 54 2mg 54 mmol L 54 teriparatide 54 idarubicin 54 lamivudine refractory patients 54 plasma glucose 54 ACE inhibitor 54 abatacept 54 log# 54 nadolol 54 ACTEMRA 54 visilizumab 54 mg/m2 54 PEG Intron ® 54 Secondary endpoints include 54 NRTI 54 attain statistical significance 54 corrected QT interval 54 celecoxib 54 nab paclitaxel 54 pegylated interferon alfa 54 Secondary endpoints included 54 inhaled fluticasone 54 exemestane 54 MIRAPEX 54 extrapyramidal symptoms 54 pegIFN 54 anti androgen 54 CrCl 54 warfarin 54 disease progression 54 confidence interval #.#-#.# 54 zafirlukast 54 pentoxifylline 54 log# copies mL 54 oral antidiabetes drugs 54 unfractionated heparin UFH 54 FOSRENOL R 54 creatinine clearance 54 HAART regimen 54 TLUS 54 pomalidomide 54 microgram dose 54 randomized double 54 plus prednisone 54 Detrol LA 54 depressive symptoms 54 plus prednisone prednisolone 54 etravirine 54 fluvastatin 54 % CI #.#-#.# [007] 54 plus OBT 54 clinically meaningful improvements 54 BARACLUDE 54 VFEND 54 mirtazapine 54 RGT arm 54 posttreatment 54 ARICEPT 54 golimumab CNTO 54 partial remissions 54 Kaplan Meier analysis 54 docetaxel prednisone 54 baseline A1C 54 losartan 54 mg m² 54 mesalamine granules 54 pyrazinamide 54 nevirapine Viramune 54 seropositive patients 54 QTcF 54 Thal Dex 54 HbA 1c 54 highly emetogenic 54 log# reduction 54 primary hypercholesterolemia 54 laboratory abnormalities 54 Lantus R 54 NNT = 54 rasagiline 54 ACR# [002] 54 intra articular injection 54 null responders 54 buproprion 54 mmHg 54 plasma urate 54 daily subcutaneous injections 54 abacavir 54 salmeterol fluticasone propionate 54 ADAS cog 54 thromboembolic 54 Baseline characteristics 54 antiretroviral naive 54 esomeprazole Nexium 54 Hazard Ratio 54 low dose cytarabine 54 tiotropium bromide 54 sitagliptin 54 Hazard Ratio HR 54 patients evaluable 54 GERD symptom 54 tenecteplase 54 NATRECOR ® 54 beclomethasone 54 boceprevir 54 PegIFN RBV 54 entecavir 54 glycoprotein IIb IIIa inhibitor 54 mg kg belimumab 54 lubiprostone 54 mL kg 54 BoNTA 54 Free Survival PFS 54 secondary efficacy endpoints 54 administered orally 54 LATUDA 54 DAS# scores 54 inhaled steroid 54 vasomotor symptoms 54 povidone iodine 54 baminercept 54 CYPHER Stent 54 vaginal progesterone gel 54 intravenous dose 54 achieve statistical significance 54 dizziness nausea diarrhea 54 low dose Iluvien 54 postop 54 noninferiority 54 atorvastatin 54 rFVIIa 53 trials RCTs 53 tegaserod 53 BEACOPP 53 FluCAM 53 postdose 53 haloperidol 53 spironolactone 53 nonobese 53 aspirin heparin 53 discontinuations 53 lanthanum carbonate 53 VaD 53 peginterferon alpha 2a 53 NEVO ™ 53 intravenous dosing 53 statistically significant superiority 53 tricyclic antidepressants 53 symptomatic VTE 53 normotensive 53 VELCADE melphalan 53 oral antidiabetic medication 53 rapid virologic response 53 #mg ritonavir 53 budesonide formoterol 53 echinacea tablets 53 beta blocker therapy 53 trastuzumab 53 double blind placebo 53 dose titration 53 zopiclone 53 -#.# mg dL [001] 53 Nasacort AQ 53 Apidra ® 53 rt PA 53 ADAS Cog 53 adriamycin 53 rhGH 53 interferon ribavirin 53 amphotericin B 53 dacarbazine chemotherapy 53 LTRA 53 HBeAg positive patients 53 milrinone 53 mg Androxal 53 alanine aminotransferase 53 darunavir r 53 μg mL 53 mcg kg REBETOL 53 dexrazoxane 53 VAPRISOL 53 reboxetine 53 melphalan prednisone 53 placebo controlled studies 53 interpersonal psychotherapy 53 pemetrexed 53 RRMS patients 53 5 fluorouracil 53 glycated hemoglobin levels 53 iniparib 53 log# IU mL 53 guanfacine 53 fluticasone propionate FP 53 nalbuphine 53 HCTZ 53 HBeAg positive 53 YMRS 53 abiraterone acetate 53 metformin sulfonylurea 53 5mg 53 rTMS 53 gastric pH 53 SYMBICORT 53 atorvastatin Lipitor 53 oxycodone HCl 53 inhaled budesonide 53 mg/# hours 53 rosuvastatin Crestor 53 palonosetron 53 mmol l 53 dose regimen 53 irinotecan 53 tDCS 53 paliperidone ER 53 recurrent venous thromboembolism 53 ethambutol 53 p = #.# [003] 53 rHuEPO 53 DOXIL 53 pooled comparator 53 alpha blocker 53 clomiphene 53 gabapentin 53 hypoglycemic events 53 hypomagnesemia 53 GnRH agonist 53 dose clopidogrel 53 Zometa hazard 53 tamoxifen Nolvadex ® 53 azacitidine 53 binary restenosis 53 dabigatran etexilate 53 tenofovir FTC 53 doxorubicin cyclophosphamide 53 prospectively defined 53 CI #.#-#.# [002] 53 prazosin 53 intravenous diuretics 53 cangrelor 53 relapsed MM 53 antihypertensive drugs 53 Mg Uk 53 tipranavir ritonavir 53 ribavirin therapy 53 insulin degludec 53 ritonavir 53 mm Hg 53 oral corticosteroids 53 triptan 53 fasting triglyceride levels 53 ascending doses 53 AVODART 53 plus GP IIb 53 sustained virological response 53 diastolic BP 53 mg/m2 IV 53 fasting blood glucose 53 ACTOS 53 otamixaban 53 antibody titers 53 lipid lowering therapy 53 oral bisphosphonates 53 maximal doses 53 standard chemotherapy regimen 53 antiemetics 53 inhaled steroids 53 tadalafil Cialis 53 atypical antipsychotic 53 Hepsera 53 plasma uric acid 53 amisulpride 53 rabeprazole 53 lumbar spine bone 53 adalimumab Humira 53 serologically active patients 53 inflammatory lesions 53 oral antidiabetes 53 virologic 53 tranylcypromine 53 MADRS 53 FOLFIRINOX 53 epoetin alfa 53 peak plasma concentrations 53 1mg 2mg 53 ezetimibe 53 KRAS mutant tumors 53 serum phosphate levels 53 p = .# [001] 53 bupropion XL 53 canakinumab 53 telaprevir dosing 53 mapatumumab 53 FROVA 53 CC genotype 53 gout flare 53 LT NS# 53 ginkgo biloba extract 53 gp# vaccine 53 ONGLYZA 53 cetuximab 53 peg interferon 53 corticosteroids 53 verum acupuncture 53 relapsers 53 voriconazole 53 lipid parameters 53 PRADAXA #mg 53 seroprotection 53 oral corticosteroid 53 estramustine 53 verapamil 53 % Confidence Interval 53 nonrandomized 53 plasma folate 53 systemic corticosteroid 53 MoxDuo TM IR 53 ciclosporin 53 CR CRu 53 p = ns 53 GSK# [001] 53 sUA 53 ng ml 53 aromatase inhibitor therapy 53 VIRAMUNE XR 53 tamoxifen therapy 53 systemic absorption 53 intravenous doses 53 fluoxetine Prozac 53 SCIg 53 intima media thickness 53 Fasting plasma glucose 53 tenofovir Viread 53 PREZISTA r arm 53 aspirin 53 SSRI SNRI 53 simvastatin ezetimibe 53 chemoradiotherapy 53 microgram kg 53 liver histology 53 intravitreal injections 53 cisplatin 53 fatigue asthenia 53 oral alendronate 53 neutrophil counts 53 NIH CPSI 53 medroxyprogesterone acetate 52 nitazoxanide 52 thalidomide dexamethasone 52 Atacand

Back to home page